Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

Arrowhead claims safety edge over Ionis as triglyceride battle draws closer

30 August 2026 · By · Wire by Fusion42

Published

30 August 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at endpoints.news →

◆ Verified

Fusion42 · 30 August 2026 · Fusion42 review

Arrowhead's RNA interference drug Redempplo demonstrated superior safety and effectiveness compared to Ionis Pharmaceuticals' treatment in two late-stage trials for triglyceride lowering.

This Wire brief sits within Fusion42's coverage of Biotech.

◆ ◆ The Wire takeaway

You must re-evaluate competitive positioning as Arrowhead’s safer RNA interference drug opens a new challenge to Ionis in triglyceride therapies, potentially shifting market share and partnership interest.

◆ Coverage

1 source · 30 Aug 2026

◆ Related on Wire

◆ Topics

Biotechpharmaclinical-trialsRNAidrug-safetytriglycerides